What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Puntos clave

• This research aims to evaluate the incidence and clinical significance of dry eye disease in patients receiving immune checkpoint inhibitors.
• Conducted a systematic review and meta-analysis of existing studies.
• Analyzed pooled estimates of dry eye disease incidence across diverse study designs.
• Considered subgroup analyses for combination therapy and lung cancer cohorts.
• Dry eye disease occurs in approximately 1 in 50 patients treated with immune checkpoint inhibitors.
• Incidence rates vary significantly depending on study design and diagnostic approaches.
• Combination therapy and lung cancer patient groups show higher reported rates of dry eye disease.